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Hyperglycaemia induces metabolic dysfunction
and glycogen accumulation in pancreatic b-cells
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Insulin secretion from pancreatic b-cells is impaired in all forms of diabetes. The resultant
hyperglycaemia has deleterious effects on many tissues, including b-cells. Here we show that
chronic hyperglycaemia impairs glucose metabolism and alters expression of metabolic genes
in pancreatic islets. In a mouse model of human neonatal diabetes, hyperglycaemia results in
marked glycogen accumulation, and increased apoptosis in b-cells. Sulphonylurea therapy
rapidly normalizes blood glucose levels, dissipates glycogen stores, increases autophagy and
restores b-cell metabolism. Insulin therapy has the same effect but with slower kinetics.
Similar changes are observed in mice expressing an activating glucokinase mutation, in
in vitro models of hyperglycaemia, and in islets from type-2 diabetic patients. Altered b-cell
metabolism may underlie both the progressive impairment of insulin secretion and reduced
b-cell mass in diabetes.
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T
he hallmark of the pancreatic b-cell is its ability to respond
to glucose with increased insulin secretion. This process
is impaired in diabetes, leading to chronic elevation of
the blood glucose concentration. Long-term hyperglycaemia has
deleterious effects in many tissues. In b-cells, it causes a reduction
in insulin release, in insulin granule density and in b-cell
number, a phenomenon termed glucotoxicity1,2. Numerous
studies have examined the effects of hyperglycaemia on b-cell
structure and function, both in vitro, using isolated islets or
insulin-secreting cell lines, or in vivo, using obese diabetic animal
models, but few have examined the time dependence and
reversibility of the effects of hyperglycaemia, or the mechanisms
involved. We have therefore investigated the progressive
changes in b-cell dysfunction produced by diabetes, and their
reversal, using an inducible mouse model of neonatal diabetes
caused by an activating mutation in the ATP-sensitive potassium
(KATP) channel3,4.
The KATP channel couples blood glucose levels to insulin
secretion by virtue of its sensitivity to changes in b-cell
metabolism. Elevation of blood glucose stimulates glucose uptake
and metabolism by the b-cell, thereby increasing intracellular
ATP. This closes KATP channels and leads to b-cell
depolarization, calcium influx and insulin granule exocytosis5.
Gain-of-function mutations in either the Kir6.2 (KCNJ11) or
SUR1 (ABCC8) subunit of the KATP channel are a major cause of
neonatal diabetes, a rare inherited disorder characterized by the
development of diabetes within the first 6 months of life6,7.
In neonatal diabetes, failure of the KATP channel to close in
response to metabolically generated ATP prevents b-cell electrical
stimulation and insulin release, causing hypoinsulinaemia
and hyperglycaemia6–8. Sulphonylurea drugs are used to treat
patients with neonatal diabetes as they selectively block the open
KATP channels9. This results in far better glycaemic control,
with fewer fluctuations in plasma glucose concentration, a lower
HbA1C, a reduced incidence of hypoglycaemia and a simpler
medication regime10–15.
Recent studies demonstrate that chronic hyperglycaemia in
mice expressing an activating KATP channel mutation results
in striking b-cell remodelling3,16. This is characterized by a
marked loss of insulin granules, a reduction in islet number and
dysregulation of a- and b-cell identity genes3,16.
We now show that diabetes causes marked changes in b-cell
carbohydrate metabolism and glucose-stimulated ATP produc-
tion as soon as 24 h after exposure to hyperglycaemia. Prolonged
diabetes also resulted in substantial glycogen accumulation that
led to increased b-cell apoptosis. Restoring euglycaemia induced
autophagy, rapidly dissipated glycogen stores, normalized
metabolism and reversed many of the gene expression changes.
Analysis of mice expressing an activating mutation in glucokinase
revealed that enhanced glucose metabolism, rather than glucose
per se, was responsible for the changes in gene expression
and glycogen storage. Glycogen accumulation was observed also
in islets of patients with type-2-diabetes. The progressive
impairment of b-cell function with chronic hyperglycaemia helps
explain why sulfonylurea therapy is more effective in neonatal
diabetes patients with shorter diabetes duration10, and has
implications not only for the aetiology and treatment of
neonatal diabetes, but also for other forms of diabetes.
Results
KATP channel activation results in rapid diabetes. We
investigated the time course of the b-cell changes induced by
hyperglycaemia and its reversal in vivo in an inducible mouse
model of neonatal diabetes (bV59M)3. Nutrient-stimulated
insulin secretion was switched off in bV59M mice at 12–14
weeks of age by b-cell-specific expression of an activating
KATP channel mutation (Kir6.2-V59M) commonly found in
human neonatal diabetes3,7. This resulted in blood glucose levels
428mM within 2 days. Euglycaemia could be restored by
subcutaneous administration of the sulphonylurea glibenclamide,
which closes the open KATP channels, or by insulin3.
No differences in plasma lipid levels were found between
control mice and diabetic bV59M mice (Supplementary Fig.1).
Free fatty acids, total serum cholesterol, HDL cholesterol,
LDL/VHDL cholesterol were unchanged. Triglycerides were
slightly but not significantly elevated. Aminoalanine transferase
(ALT) activity, a marker of liver damage, was also unaffected.
Thus the changes we observe are a result of hyperglycaemia/
hypoinsulinaemia and not a secondary consequence of altered
lipid metabolism.
Diabetes duration impacts b-cell function. Diabetes was
associated with progressive changes in b-cell mass and ultra-
structure. b-cell mass, assessed as the percentage of insulin
staining per cm2 of pancreas, was markedly lower in islets from 2-
or 4-week diabetic bV59M mice (Fig. 1a). Islet density also fell,
reflecting a decrease in both islet number and size (Fig. 1b). The
reduction in insulin-labelled cells was paralleled by an increase in
glucagon-positive cells (Fig. 1c). There was also a time-dependent
decrease in insulin granule density, as shown by electron
microscopy (EM), and a gradual development of large areas of
unstructured cytoplasm in b-cells (Fig. 1d) that increased with the
duration of diabetes (Fig. 1e). Hyperglycaemia for 24 h, however,
had no effect on islet insulin labelling, granule number or islet
ultrastructure (Fig. 1c,d).
Blood glucose levels in diabetic bV59M mice were rapidly
normalized with either insulin3 or sulphonylurea (glibenclamide)
therapy (Fig. 2a). However, the ability of sulphonylureas to
restore euglycaemia was dependent on diabetes duration, as seen
in human patients with neonatal diabetes10. Following 2 weeks of
diabetes, glibenclamide normalized blood glucose within 24 h in
88% (7/8) of mice, but it was only successful in 47% (7/15) of
mice after 4 weeks of diabetes. Only mice in which euglycaemia
was restored within 48 h were used in this study (Fig. 2a). Islet
insulin content was unaffected at 1 week of diabetes but decreased
by 50% after 2 weeks of diabetes (Fig. 2b): in our earlier studies, it
fell by 70% after 4 weeks of diabetes3. Glibenclamide therapy both
prevented, and reversed, changes in islet insulin content (Fig. 2b).
Both glibenclamide and insulin treatment also reversed the
ultrastructural and histochemical changes induced by diabetes but
the time course was very different (Fig. 2c,d). Remarkably, in
mice exposed to 4 weeks of diabetes, b-cell ultrastructure was
completely normalized within 24 h of starting glibenclamide
therapy. By contrast, substantial areas of electrolucent cytoplasm
remained after 24 h of euglycaemia in insulin-treated mice
(Fig. 2d,e): however, these were largely absent after 1 week of
euglycaemia (Fig. 2d).
Functional consequences of altered glucose handling in b-cells.
We next explored the functional consequences of progressive
diabetes on b-cell function by measuring glucose-stimulated
changes in NAD(P)H autofluorescence and ATP content
in freshly isolated islets from control and diabetic bV59M mice.
In control islets, increasing glucose caused a clear
dose-dependent increase in both NAD(P)H autofluorescence
(Fig. 3a,b) and ATP content (Fig. 3d). By contrast, glucose
elevation elicited much smaller increases in NAD(P)H
fluorescence in islets from 24-h diabetic bV59M mice, and
minimal change after 4 weeks of diabetes (Fig. 3a,b). Similarly,
glucose did not elicit an increase in ATP content in 4-week
diabetic islets (Fig. 3d). There was no significant difference in
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms13496
2 NATURE COMMUNICATIONS | 7:13496 | DOI: 10.1038/ncomms13496 | www.nature.com/naturecommunications
ATP concentration at basal glucose (2mM) between control and
diabetic islets.
Remarkably, these effects were rapidly reversed by ex vivo
culture at low glucose. Culture of 4-week bV59M diabetic islets at
5mM glucose for 48 h partially restored both the NAD(P)H
(Fig. 3c) and ATP (Fig. 3e) responses to 20mM glucose. Addition
of the sulphonylurea gliclazide (which closes KATP channels)
produced an even greater effect. Culture of 4-week bV59M
diabetic islets at 25mM glucose, however, did not restore the ATP
response (Fig. 3e), indicating that reversal is a consequence of low
glucose rather than ex vivo culture.
The changes in b-cell metabolism induced by diabetes were
accompanied by striking changes in expression of metabolic genes.
Microarray analysis of mRNA extracted from isolated islets
demonstrated that expression of numerous genes was significantly
altered in response to 2 weeks of hyperglycaemia. Over 780 genes
were upregulated41.5-fold, and4300 genes were downregulated:
full details are given at (http://www.ebi.ac.uk/arrayexpress/
for experiment E-MTAB-5086). Importantly, many genes involved
in carbohydrate metabolism were also strongly affected (Supple-
mentary Table 1a,b).
To validate these changes in key metabolic genes, we
performed quantitative PCR using islets from control mice,
bV59M mice exposed to diabetes for 24 h or 4 weeks, and bV59M
mice exposed to 4 weeks of diabetes followed by 4 weeks of
glibenclamide therapy. We focused on genes involved in
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Figure 1 | Hyperglycaemia in bV59M mice induces progressive changes in b-cell mass and ultrastructure. (a,b) Mean islet cross-sectional area
immunostaining for insulin (a), and total islet area (b), expressed as a percentage of the total cross-sectional area of the pancreas (cm2) in control mice
(black bar; n¼8), and bV59M mice left diabetic for 2 weeks (gray bar; n¼ 5) or 4 weeks (white bar; n¼4). Data are mean±s.e.m. (5 sections per mouse,
100mm apart). *Po0.05; compared with control; one-way ANOVA followed by post hoc Bonferroni test. (c,d) Representative pancreatic sections from
control mice (column 1), bV59M mice left diabetic for 24 h (column 2), 2 weeks (column 3) and 4 weeks (column 4). (c) Islets were immunostained for
insulin (green) and glucagon (pink). Scale bars 200mm. (d) Electron microscopy. N, nucleus. U, unstructured substance. Scale bars 5 mm. Data are
representative of 3-4 mice in each case. (e) Serum glucose measurements (white circles) and area of unstructured cytoplasm in b-cells (black circles,
calculated from electron micrographs) in control, 24-h, 2-week and 4-week diabetic bV59M mice. For serum glucose measurements ‘n’ corresponds to
number of mice where, n¼ 26 (control), n¼ 6 (24-h diabetic), n¼ 6 (2-week diabetic) and n¼ 8 (4-week diabetic). For calculation of unstructured
cytoplasm ‘n’ corresponds to the number of islets from 3–8 mice where, n¼8 (control), n¼ 3 (24-h diabetic), n¼4 (2-week diabetic) and n¼4 (4-week
diabetic). Data are mean±s.e.m.
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gluconeogenesis (Fig. 3f), glycolysis (Fig. 3g), the Krebs cycle
(Fig. 3h), and mitochondrial metabolism (Fig. 3i) that were
substantially altered in the microarray data.
It is evident that some genes changed their expression within
24 h of diabetes, whereas others did not. For example, G6pc2,
Pfkfb2, Ogdh1 and Cox6a2 were significantly affected by 4 weeks
of diabetes but were unchanged by 24 h of hyperglycaemia.
Conversely, Pdk1, Fbp1, Fbp2 and Ppp1r3c were fully upregulated
within 24 h: thus, these genes may be under different
metabolic control than those that take longer to change. Some
of these gene changes were reversed by 4 weeks of
glibenclamide therapy (for example, G6pc2, Pfkfb2, Ogdh1,
Cox6a2 and Ppp1r3c) but, interestingly, many others were not
(for example, Pdk1, Fbp1, Fbp2).
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Figure 2 | Effects of hyperglycaemia reversal in bV59M mice. (a) Blood glucose levels of 4-week diabetic bV59M mice implanted with a slow release
sulphonylurea pellet at time zero for mice in which euglycaemia was established within 4 days. (b) Mean (±s.e.m.) insulin content of isolated islets (n¼4–
12 mice). Mice were implanted with either placebo or glibenclamide pellets immediately after gene induction and elevation of blood glucose to420mM.
The duration of diabetes is indicated above and that of glibenclamide therapy below. *Po0.05; *, Po0.01. NS, not significant (t-test). (c,d) Representative
pancreatic sections from 4-week diabetic bV59M mice after 24-h treatment with the sulphonylurea glibenclamide (SU reversal, left), or treatment with
insulin for 24 h (middle) or 1 week (right). (c) Islets immunostained for insulin (green) and glucagon (pink). Scale bar (200mm). (d) Electron microscopy.
N, nucleus. U, unstructured substance. Scale bars 4mm (left), 5 mm (middle, right). Data are representative of 3–4 mice in each case. (e) Mean (±s.e.m.)
area of unstructured cytoplasm in b-cells (calculated from electron micrographs of isolated islets) from 4-week diabetic bV59M mice (n¼4 islets) and
4-week diabetic bV59M mice treated for 24 h with glibenclamide (n¼4 islets) or insulin (n¼ 6 islets).
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Figure 3 | Diabetic bV59M mice have altered glucose metabolism and gene expression. (a) Representative changes in NAD(P)H autofluorescence
measured in response to 6mM and 20mM glucose from islets isolated from a control mouse (black trace) or a 4-week diabetic bV59M mouse (gray trace).
Data are normalized to the level in 1mM glucose. (b) Mean (±s.e.m.) NAD(P)H autofluorescence produced by 1mM (black bars) 6mM (gray bars) and
20mM glucose (white bars) in control islets (n¼ 7 islets from 3 mice) and islets isolated from 24h (n¼ 7 islets from 4 mice) and 4-week diabetic bV59M
mice (n¼ 9 islets from 4 mice). *Po0.05, ** Po0.01, ***Po0.001 v. 2mM glucose (t-test). (c) Mean (±s.e.m.) NAD(P)H autofluorescence produced by
1mM (black bars) 6mM (gray bars) and 20mM glucose (white bars) in islets isolated from 4-week diabetic bV59M mice and then cultured at 25mM
glucose (n¼ 5 islets), 5mM glucose (n¼8 islets) or 5mM glucose plus 2mM gliclazide (n¼8 islets) for 72h. *Po0.05, ** Po0.01, ***Po0.001 v. 2mM
glucose (t-test). (d) Mean (±s.e.m.) ATP content of control (C; n¼6 mice) and 4-week diabetic bV59M (4-week n¼ 5 mice) islets incubated for 1 h in 2mM
(black bars) or 20mM glucose (white bars). *Po0.05 versus control (t-test). (e) Mean (±s.e.m.) ATP content of islets incubated at 2mM glucose (black
bars) or 20mM glucose (white bars) for 1 h. Islets were isolated from 4-week diabetic bV59M mice (n¼4 mice) and cultured at 25mM glucose, 5mM
glucose, or 5mM glucose plus 2mM gliclazide, or 25mM glucose for 72h before experiment. *Po0.05 versus control (t-test). (f–k) Quantitative PCR of
mRNA isolated from islets from control mice (black bars; n¼6 mice) or from bV59Mmice 24h (gray bars; n¼4 mice) and 4 weeks (white bars; n¼ 7 mice)
after diabetes onset, or after 4 weeks of diabetes and 4 weeks of glibenclamide therapy (hatched bars; n¼ 7 mice). Genes assayed are involved in
gluconeogenesis (f) glycolysis (g), Krebs cycle (h), oxidative phosphorylation (i), and glycogen metabolism (j,k). Data are mean±s.e.m. *Po0.05, ** Po0.01,
***Po0.001 v. control (t-test).
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Overall, the gene changes we observed are expected to reduce
flux through the Krebs cycle and oxidative phosphorylation, and
increase gluconeogenesis. For example, downregulation of the
glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bispho-
sphatase (Pfkfb2) and upregulation of pyruvate dehydrogenase
kinase (Pdk1) would reduce entry of acetyl CoA into the Krebs
cycle (Fig. 3f,g). In addition, downregulation of the Krebs cycle
enzymes fumarase (Fh1) and oxoglutarate dehydrogenase (Ogdh1)
would decrease entry of reducing equivalents (NADH) into the
electron transport chain (Fig. 3h). This, together with the reduced
expression of cytochrome c oxidase (Cox6a2) mRNA, the last
enzyme in the electron transport chain, explains why glucose
fails to stimulate NAD(P)H and ATP production in diabetic
bV59M islets (Fig. 3i). However, ATP synthase (ATP6) did
not change.
Upregulation of the gluconeogenic genes Fbp1 and Fbp2 (which
catalyse hydrolysis of fructose 1,6-bisphosphate to fructose-6-
phosphate) and downregulation of G6pc2 (which catalyses the
hydrolysis of glucose-6-phosphate to glucose) (Fig. 3f), implies that
glucose entering the b-cell will accumulate as glucose-6-phosphate
(G6P). In turn, this will lead to glycogen storage, as G6P is a potent
allosteric stimulator of glycogen synthase17 and glucose is an
inhibitor of glycogen phosphorylase. Most enzymes directly
involved in glycogen synthesis did not change their expression
(Fig. 3j), but Ppp1r3c (PTG), which activates glycogen synthase,
was strongly upregulated after 24h (Fig. 3k).
Glycogen accumulation in diabetic b-cells. Collectively, these
gene changes, together with the enhanced substrate availability
and the impaired ATP production, suggest that glucose entering
diabetic bV59M b-cells will be stored as glycogen. This was
investigated by both light microscopy (using Periodic Acid Schiff
(PAS) staining) and electron microscopy.
No PAS staining was detected in control b-cells (Fig. 4a) or
b-cells exposed to hyperglycaemia for 24 h (Fig. 4b). However,
considerable glycogen staining was evident in b-cells exposed to
high glucose for 42 weeks (Fig. 4c). After 4 weeks of diabetes,
many b-cells appeared ‘clear’ or ‘empty’ (Fig. 4d), due to loss of
glycogen during processing18. Such loss becomes more evident
when glycogen deposits are very substantial and leads to an
apparent decrease in glycogen staining and the appearance of an
‘empty’ cytoplasm. Strikingly, no glycogen was detected in 4-week
diabetic bV59M b-cells after 24 h of glibenclamide therapy
(Fig. 4e). By contrast, substantial glycogen staining remained in
insulin-treated mice after 24 h of euglycaemia (Fig. 4f), and this
was not fully abolished even after 1 week of euglycaemia (Fig. 4g).
Ultrastructural studies using lead-citrate fixation to preserve
glycogen revealed extensive deposits of glycogen particles in most
b-cells of bV59M islets after 4 weeks of hyperglycaemia (Fig. 4h,i).
Indeed, in some b-cells the glycogen content was so excessive that
it constituted the majority of the cytoplasm and caused distortion
of the nucleus and endoplasmic reticulum. However, no glycogen
was found in control islets. It is important to note that glycogen is
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not detected using conventional EM fixatives, as it is water soluble
and easily washed out of cells during fixation. This leaves large
regions of electrolucent ‘unstructured’ cytoplasm, like those shown
in Fig. 4j (and Figs 1d and 2d, which correspond to the ‘empty’
cells shown in Fig. 4d).
Metabolic dysfunction disrupts protein turnover. Glycogen
exists as a large macromolecular complex with numerous
associated proteins, and its accumulation in other tissues is
controlled by autophagy as well as metabolism19,20. We therefore
next explored whether autophagy is impaired in diabetic bV59M
islets.
Proteins marked for autophagic degradation are first
ubiquitinated and then targeted to the autophagosome via p62,
and both ubiquitin and p62 commonly accumulate in cells in
which autophagy is inhibited21–25. Several lines of evidence
indicate that autophagic flux is impaired in 4-week diabetic
bV59M islets. First, there was a marked increase in ubiquitin
protein aggregates, at both light microscope and ultrastructural
levels (Fig. 5a-c). Secondly, p62 protein was also increased
(Fig. 5d,e). Interestingly, ubiquitin and p62 colocalized with
glycogen deposits in 4-week diabetic bV59M b-cells (Fig. 5c,d,
Supplementary Fig. 2A,B). Thirdly, LC3B-II protein levels were
enhanced (Fig. 5e; Supplementary Fig. 2A,B). Finally, transcript
levels of beclin-1, which is known to promote autophagy26, were
significantly reduced (Fig. 5f).
Autophagy was very low in control b-cells and no change in
the number of autophagosomes could be detected in 4-week
diabetic bV59M b-cells (Fig. 5g). However, restoration of
normoglycaemia led to a dramatic increase in the number of
autophagosomes (Fig. 5g,h). Glycogen granules were found in
both autophagosomes (Fig. 5i) and lysosomes (Fig. 5l), which
suggests that when diabetes is reversed, glycogen is degraded, at
least in part, via the autophagic–lysosomal system.
Hyperglycaemia induces metabolic dysfunction in T2DM. We
next explored whether the metabolic changes we observed in
bV59M islets are a general feature of hyperglycaemia. Glycogen
accumulation was observed in human islets from donors with
type-2 diabetes at both light (Fig. 6a) and electron (Fig. 6b)
microscopy levels. b-Cells with large areas of ‘empty’ cytoplasm,
corresponding to regions where glycogen was washed away
during processing, were also observed in islets from type-2 dia-
betic donors (* marked areas in Fig. 6a). Glycogen also accu-
mulated in b-cells following in vitro culture of islets from non-
diabetic human donors (Fig. 6c-e) or control mice
(Supplementary Fig. 3) for 48 h at 25mM glucose. Accumulation
of glycogen by control mouse islets cultured at high glucose has
been reported previously27–29. The NAD(P)H response to glucose
elevation was also impaired in mouse islets cultured at 25mM
glucose (Supplementary Fig. 3). As observed for diabetic bV59M
b-cells, glycogen stores were rapidly dissipated when islets were
returned to 5mM glucose for 24 h (Fig. 6e; Supplementary Fig. 3).
Similar results were found for INS-1 cells: culture at high glucose
caused glycogen accumulation, which was reversed when cells were
subsequently cultured at low glucose (Fig. 6f–h; Supplementary
Fig. 4). In INS-1 cells treated with the lysosomal inhibitors E-64d
or pepstatin A, glycogen was found in defined puncta correspond-
ing to LAMP2 positive lysosomes (Supplementary Fig. 5). The gene
expression changes found in diabetic bV59M islets were also
largely mirrored in INS-1 cells treated with high glucose for 24 h.
However, in contrast to 4-week diabetic bV59M islets, almost all
gene expression changes were reversed by 24-h culture at 2mM
glucose (Fig. 7i–m).
To determine if altered glucose metabolism underlies glycogen
formation, we used a mouse model that expresses an activating
mutation in the glucokinase gene (GCK) specifically in adult
b-cells (mutGCK mice)30. Glucokinase catalyses the phosphory-
lation of glucose to glucose-6-phosphate, the rate-limiting step in
glucose metabolism and mutGCK mice display hypermetabolism
and enhanced insulin secretion despite normal blood glucose
levels30 Within 4 days of transgene induction, we found substantial
accumulation of glycogen in b-cells by both light (Fig. 6n) and
electron (Fig. 6o) microscopy. Furthermore, RNAseq analysis of
islets isolated from mutGCK mice showed similar gene changes to
those found in bV59M islets and INS-1 cells cultured at high
glucose concentrations. This included elevation of Ppp1r3c
(3.4-fold), Pdk1 (2.3-fold), Fbp2 (4-fold), and Aldob (68-fold),
and a decrease in G6pc2 (2.4-fold), Cox6a2 (1.7-fold), and Pfkfb2
(1.5-fold). This suggests that glucose metabolism, rather than
glucose per se, drives both glycogen formation and the metabolic
gene expression changes observed in diabetic b-cells.
Impaired metabolism and glycogen storage underlie b-cell death.
It is well established that diabetes or impaired autophagy leads
to apoptosis in b-cells31,32. Marked b-cell apoptosis is also
observed in mutGCK mice following prolonged activation
of the transgene30. We therefore explored whether altered
metabolism and glycogen accumulation contribute to b-cell
death in diabetes.
In a previous study3, we found no obvious increase in the
number of apoptotic nuclei after 4 weeks of diabetes when
assessed by nuclear morphology (chromatin condensation) with
electron microscopy. However, this approach may underestimate
the extent of apoptosis as few cells can be examined, apoptosis
and cell debris removal are quickly complete, and earlier
time points were not assessed. Thus, we examined earlier steps
in the b-cell death pathway, which are more readily detectable.
Figure 7a,b shows that cleaved caspase-3 was not present in
control islets but significant labelling was detected in bV59M
islets after 2 weeks of hyperglycaemia, by which time glycogen
accumulation was extensive. Furthermore, active caspase-3 was
found with glycogen in insulin-positive cells (arrow), but was
absent in glycogen-negative cells (arrowhead) and in glucagon-
positive a-cells (which did not accumulate glycogen (Fig. 7d).
Apoptotic bodies (‘cellular blebbing’), a hallmark of apoptosis
were also seen in electron micrographs of b-cells of 4-week
diabetic bV59M islets (Fig. 7e,f). Interestingly, these apoptotic
bodies were filled with glycogen granules when measures were
taken to preserve glycogen (Fig. 7f).
To further examine the relationship between glycogen
accumulation and b-cell death, we manipulated glycogen levels
independently of the ambient glucose level. First, we used the
antidiabetic drug metformin, which inhibits glycogen synthesis33,
to reduce glycogen levels at high external glucose concentrations.
In the presence of 25mM glucose, metformin prevented glycogen
accumulation in INS-1 cells (Fig. 7g,h) and reduced caspase-3
activation and apoptosis (Fig. 7i). Furthermore, expression of
Ppp1r3c (PTG) was reduced (Fig. 7j). This protein targets protein
phosphatase-1 (PP1) to glycogen and its expression is closely
linked to glycogen content34. In cells in which glycogen had
already accumulated, subsequent addition of metformin did not
affect glycogen or cleaved caspase-3 levels (Supplementary Fig. 6).
This suggests metformin, at least at the concentration we used,
does not itself reduce caspase-3 activation.
Secondly, we further enhanced glycogen levels at high glucose
concentrations by silencing UDP-glucose-pyrophosphorylase-2
(UGP2) in INS-1 cells. A significant decrease in both UGP2
mRNA (Fig. 7k) and protein (Fig. 7l; Supplementary Fig. 7A) was
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observed following 72 h of knockdown. We had expected this to
lower glycogen levels, because UGP2 catalyses the addition of
UDP to glucose-1-phosphate to promote glycogen formation.
Unexpectedly, however, it led to a paradoxical rise in glycogen at
high glucose (Fig. 7m,n; Supplementary Fig. 8). We attribute this
to the fact that Ppp1r3c expression was enhanced (Fig. 7o).
Importantly, the elevated glycogen was accompanied by increased
caspase-3 activation (Fig. 7p; Supplementary Fig. 7B).
Taken together, these studies demonstrate that caspase activa-
tion correlates with glycogen content, suggesting that excessive
glycogen accumulation may mediate, at least in part, enhanced
b-cell death in response to chronic hyperglycaemia.
Discussion
Our data show that hyperglycaemia results in a progressive
impairment of b-cell carbohydrate metabolism and metabolic gene
expression that begins within 24h of exposure to high blood
glucose (Fig. 8). As diabetes duration increases, insulin granule
density decreases and glycogen accumulates to such an extent that
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siRNA 72 hrs previously and then cultured for 48-h at 25mM glucose (n¼ 3).
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it causes gross distortion of b-cell ultrastructure. Changes in gene
expression, metabolic pathways and impaired autophagy may
contribute to glycogen accumulation. Studies of mutGCK mice
further indicate that increased glucose metabolism, rather than
glucose per se, drives glycogen synthesis and many of the changes
in metabolic gene expression. Impaired autophagy and increased
cleaved caspase-3 suggest apoptotic pathways are also stimulated.
Similar changes to those seen in islets of bV59M mice in vivo were
also observed in control mouse islets, in islets from non-diabetic
human donors and in INS-1 cells exposed to hyperglycaemia
in vitro.
Restoration of euglycaemia by glibenclamide rapidly restored
normal glucose metabolism, dissipated glycogen stores, stimulated
autophagy and inhibited apoptosis. This was more easily achieved
after short-term hyperglycaemia. The progressive decline in b-cell
structure, function and insulin content caused by chronic
hyperglycaemia likely account for the reduced ability of bV59M
mice with a longer duration of diabetes, and of older patients with
neonatal diabetes10, to respond to sulphonylurea therapy.
In vivo, hyperglycaemia is linked with hypoinsulinaemia,
making it difficult to distinguish which is causative with certainty.
However, because the insulin concentration of the culture medium
was constant in our in vitro studies of islets and INS-1 cells, the
changes we observed must be a function of hyperglycaemia. This is
supported by experiments using partially pancreatectomized rats
where expression of many genes important for glucose-stimulated
insulin release, and a range of b-cell specific transcription factors,
was altered by hyperglycaemia and restored by correction of blood
glucose alone with phloridzin2.
Analysis of a mouse model with an activating glucokinase
mutation targeted to the b-cell30 revealed that enhanced glucose
metabolism, rather than glucose per se, drives glycogen formation.
This is evident because mutGCK animals were normoglycaemic at
the age at which we studied them. In b-cells exposed to high
glucose27, glucose-6-phosphate (G6P) increases rapidly because
intracellular glucose tracks the extracellular concentration and
glucokinase is a high capacity, high Km enzyme. Despite their
normal blood glucose levels, G6P is also expected to be elevated in
mutGCK mouse b-cells, due to the enhanced glucokinase
activity. Glucose-6-phosphate is a potent allosteric activator
of glycogen synthase17 and both glucose and G6P inhibit
glycogen phosphorylase35. These allosteric effects on enzyme
activity potentiate glycogen accumulation, ensuring that it is
rapidly initiated when glucose increases and quickly reversed when
glucose levels fall.
Glycogen stores are only evident when measures are taken to
preserve glycogen during fixation and processing; if this is not
done, glycogen loss leads to areas of unstructured cytoplasm that
have been variously described as ‘clear’, ‘empty’ or ‘vacuolated’ at
the light microscope level. Such ‘empty b-cells’ have been
reported previously in patients with severe uncompensated
diabetes36 and in numerous more recent studies of pancreatic
islets from diabetic mouse models16,21,22,24,25,37. These studies
used fixation methods that were not designed to preserve
glycogen, suggesting that the ‘empty’ cells observed may not, in
fact, have been empty but contained glycogen that was lost during
processing. This would also argue that altered metabolism and
glycogen accumulation is a feature of all diabetic b-cells.
Small amounts of glycogen can be beneficial to a cell, by
providing an energy store at times when the substrate supply
falls. However, excessive glycogen may be deleterious: in
other cell types it is associated with cell death. For example,
glycogen accumulation in human diabetic nephropathy38,39 is
accompanied by enhanced apoptosis40, and in neurones, glycogen
accumulation triggers a decrease in autophagy that leads to cell
death41–43. The marked increase in cleaved caspase-3 in
glycogen-positive b-cells, and the gross distortion of b-cell
ultrastructure we observed suggests excessive glycogen
deposition may also be deleterious in b-cells.
In support of this idea, we found a strong positive correlation
between the extent of cleaved caspase-3, the density of b-cell
glycogen granules and the level of PTG (Ppp1r3c) expression that
was independent of extracellular glucose. When the glucose
concentration was held constant at 25mM, metformin reduced
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sensitive Kþ channel (KATP) and thereby promotes membrane depolarization and insulin secretion. (b) Chronic hyperglycaemia leads to impaired oxidative
metabolism and reduced ATP generation in response to glucose, thereby preventing KATP channel closure, electrical activity and insulin secretion.
Hyperglycaemia leads to elevation of G6P, which stimulates glycogen synthase and also leads to elevation of Ppp1r3c (PTG), both of which promote
glycogen accumulation. Hyperglycaemia may also impair autophagy, further increasing glycogen storage and enhancing b-cell death. KATP, ATP-sensitive
Kþ channel. G6P, glucose-6-phosphate. PTG, protein targeting to glycogen (Ppp1r3c). GS, glycogen synthase. GP, glycogen phosphorylase.
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both PTG levels and glycogen accumulation, and led to a decrease
in cleaved caspase-3. Conversely knockdown of UGP2 increased
PTG and glycogen at 25mM glucose further, while simulta-
neously elevating cleaved-caspase-3. This suggests that increased
b-cell glycogen may lead to caspase-3 activation and subsequent
b-cell apoptosis. Indeed, we observed a striking accumulation of
glycogen in apoptotic bodies in bV59M islets. It is likely that the
deleterious effect of glycogen on the b-cell varies with the extent
of its accumulation, and thus with the duration and degree of
diabetes; and that there is a threshold below which glycogen has
no adverse action.
Currently it is widely assumed that b-cells do not store or
metabolise glycogen. Indeed, a role for glycogen in normal b-cell
function has recently been excluded by examining the effects of
overexpression of PTG and knockdown of glycogen synthase I in
mice44. However, this does not exclude a role for glycogen
accumulation in diabetes45. Indeed, our data provide evidence
that in combination with metabolic dysfunction and changes in
autophagy, glycogen accumulation in severe uncompensated
diabetes may promote b-cell loss via increased caspase-
dependent apoptosis, and thereby enhance the hyperglycaemia.
The presence of glycogen in islets from type-2 diabetic patients,
further suggests that glycogen accumulation may contribute to
b-cell failure in diabetes.
Glycogen accumulation implies a change in glucose handling by
the b-cell. Our data demonstrate that chronic hyperglycaemia
produces a dramatic change in b-cell metabolism, such that after
4 weeks of diabetes glucose fails to elevate NAD(P)H or ATP in
bV59M islets. Failure of glucose to elevate NAD(P)H in diabetic
mice carrying an activating Kir6.2 mutation has also been reported
previously46. As NAD(P)H signals are principally mitochondrial in
origin47, our data indicate that hyperglycaemia impairs oxidative
metabolism, which accounts for the reduction in glucose-
stimulated ATP production and the diversion of glucose into
glycogen. At least some of the marked changes we observed in the
expression of key metabolic genes may underlie the altered ATP
and NAD(P)H responses to glucose.
It is remarkable that, in vivo, all glycogen disappears from the
b-cell within 24 h of normoglycaemia produced by sulphonylurea
therapy, indicating glycogen breakdown is enhanced and/or
glycogen synthesis is reduced. Both G6pc2 and Ppp1r3c are
among the genes whose expression levels are rapidly restored by
normoglycaemia. In combination with the reduced substrate
concentration and restoration of normal metabolism (see below),
these changes in gene expression are expected to lead to reduced
glycogen synthesis when euglycaemia is restored. Our data also
provide evidence that glycogen is broken down via autophagy
when blood glucose is normalized. This has been demonstrated
previously in other tissues19, but not in b-cells.
Insulin was also able to reverse the diabetes-induced changes in
islet insulin content and glycogen, but took longer to do so. This
likely reflects the ability of sulphonylureas to promote membrane
depolarization and calcium entry, which in turn facilitates
activation of Ca2þ -dependent metabolic enzymes such as
mitochondrial dehydrogenases and glycogen phosphorylase48,49.
Importantly, the glucose-stimulated increases in NAD(P)H and
ATP in bV59M islets, like the glycogen accumulation, were
restored within 48 h of normoglycaemia. Yet despite the rapid
restoration of oxidative metabolism, the expression levels of some
metabolic genes were not normalized, even after 4 weeks of
euglycaemia. Changes in expression of these specific genes therefore
may not be the only factor regulating glucose-stimulated ATP
production. The data also raise the possibility that hyperglycaemia
induces a form of metabolic reprogramming, in which some gene
expression changes are either not reversed, or require lower glucose
concentrations or longer time periods, to do so.
It is noteworthy that all the hyperglycaemia-induced changes
in gene expression in INS-1 cells were fully reversed on return to
low glucose, whereas this was not the case for those caused by
4-weeks of diabetes in vivo. This may reflect the longer duration
of diabetes in vivo, or the fact that the return glucose
concentration was lower and more stable in the INS-1 cell
experiments. The differences observed in cultured cells emphasize
the importance of in vivo experiments. Chronic hyperglycaemia
cannot be mimicked in vitro as INS-1 cells die when exposed to
425mM glucose for more than a few days. Similarly, cultured
islets may become ischaemic in the islet core, due to the lack of
vascular perfusion. Thus in both cases long-term changes in
b-cell structure and function due to diabetes cannot be faithfully
recapitulated in vitro.
Many of the changes seen in bV59M mice are also found in
islets isolated from patients with type-2 diabetes (T2DM). Similar
alterations in insulin content/staining50–52 and expression of key
metabolic genes (for example, fructose bisphosphatase53) have
been reported. The marked decrease in glucose-stimulated ATP
production we observe in bV59M islets is also seen in T2DM
islets54, and would be expected to impair insulin secretion.
Although this cannot be demonstrated in bV59M islets (because
KATP channel activation prevents ATP-induced membrane
depolarization) it likely contributes to impaired glucose-
stimulated insulin release in T2DM. We also found significant
glycogen stores in patients with T2DM who had documented
poor glycaemic control. Early studies of islets isolated from
patients with uncompensated diabetes (who died of diabetic
coma) support this finding36. These data provide evidence that
type 2 diabetes is associated with impaired b-cell metabolism that,
at least in part, derives from the elevated blood glucose. Our
results also reveal that, in mice, metformin has a protective effect
on both glycogen accumulation and b-cell death induced by high
glucose. It is possible that this may contribute to the efficacy of
this drug in treating type-2 diabetes.
In conclusion, hyperglycaemia in bV59M mice induces
profound metabolic dysfunction in b-cells. This is evidenced by
progressive changes in metabolic gene expression profiles,
decreased oxidative metabolism, impaired glucose-stimulated
ATP production and glycogen accumulation. Prolonged
exposure to hyperglycaemia also leads to loss of b-cells via
caspase-dependent apoptosis. Studies on mice with an activating
GCK mutation suggest that increased glucose metabolism drives
most of these changes. Glycogen deposits were also found in the b-
cells of patients with poorly controlled type-2 diabetes, and may
contribute to impaired b-cell function in type-2 diabetes. Provided
diabetes duration was short, restoration of euglycaemia dissipated
glycogen stores and restored b-cell metabolism. However, many of
the diabetes-induced changes in gene expression were not reversed.
It is possible this will make the b-cell more susceptible to a
subsequent metabolic insult. It was also more difficult to reverse
diabetes of longer duration. Thus our data highlight the
importance of good glycaemic control not only in patients with
neonatal diabetes, but also those with type-2 diabetes.
Methods
Animal care. All experiments were conducted in accordance with the UK Animals
Scientific Procedures Act (1986) and University of Oxford ethical guidelines. Mice
were housed in same-sex littermate groups of 2–8 animals, in a temperature and
humidity controlled room on a 12-h light-dark cycle (lights on at 07:00). Regular
chow food (63% carbohydrate, 23% protein, 4% fat; Special Diet Services, RM3)
was freely available. Water was available at all times. Because untreated diabetic
mice are polyuric, they were maintained on high absorbency bedding.
Generation of genetically modified mice. Mice expressing the Kir6.2-V59M
transgene in insulin-secreting cells (bV59M mice) were generated using a Cre-lox
approach, as previously described3. Expression was induced in 12–14 week-old
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male and female mice with a mixed (C3H, C57BL/6, 129/sv) genetic background by
a single subcutaneous injection of 0.4ml of 20mgml 1 tamoxifen in corn oil
(Sigma). Hyperglycaemia was maintained for 2 or 4 weeks. Some animals were then
implanted subcutaneously with either a slow-release glibenclamide pellet
(Innovative Research of America) or a placebo pellet containing vehicle but no
drug, under general anaesthesia (2% isoflurane, Animal Care Ltd.). Only mice in
which normoglycaemia was restored within 48 h were used in the reversal studies,
unless otherwise stated. Littermates (wild-type mice, RIPII-Cre-ER mice and mice
expressing only the floxed Kir6.2-V59M gene4) were used as controls. Genotypes
were identified by PCR using genomic DNA isolated from ear biopsies (DNeasy
Blood and Tissue kit; QIAGEN). The presence of the Kir6.2-V59M mutant gene
was confirmed using the following set of primers: P1, 50-AAAGTCGCTCTGA
GTTGTTATC-30 ; P2, 50-GATATGAAGTACTGGGCTCTT-30 ; and P3, 50-GCA
TCGCCTTCTATCGCCT-30 . These amplify a 590-bp amplicon from the WT
ROSA26 allele but a 460-bp product from the targeted allele. The presence of the
RIP-Cre gene was confirmed by the amplification of an approximately 230-bp
product, using forward ACGAGTGATGAGGTTCGCA and reverse ATGTTTAG
CTGGCCCAAATGT primers. For both genes, PCR conditions were 94 C for
3min, followed by 45 cycles of 94 C for 30 s, 57 C for 45 s, 72 C for 1min 30 s.
This was followed by a final extension at 72 C for 10min.
Mice expressing an activating mutation in the glucokinase gene (mutGCK mice)
were generated as described previously30.
Microarray studies. Mice were killed by cervical dislocation, the pancreas
removed, and islets isolated by liberase digestion and handpicking3. Total RNA was
extracted immediately using QIAshredders followed by the RNeasy Mini Kit
(Qiagen), including an on-column DNase digestion step to remove traces of
genomic DNA. RNA concentration was determined using a NanoDrop neonatal
diabetes (ND)-1000 spectrophotometer (Thermo Scientific), and its integrity46.0
verified with an Agilent 2100 BioAnalyzer.
Labelled sense ssDNA for hybridization was generated from 200 ng starting
RNA with the Ambion WT Expression Kit, the Affymetrix WT Terminal Labelling
and Controls Kit and the Affymetrix Hybridization, Wash, and Stain Kit, according
to the manufacturer’s instructions. Sense ssDNA was fragmented and the
distribution of fragment lengths measured on a BioAnalyzer. The fragmented
ssDNA was labelled and hybridized to the Affymetrix GeneChip Mouse Gene 1.0
ST Array (Affymetrix). Chips were processed on an Affymetrix GeneChip Fluidics
Station 450 and Scanner 3000.
Microarray data were normalized using GeneSpring GX (Agilent). Differentially
expressed genes were identified using Student’s t-test with a P value cut off of
r0.05 and a fold change difference of Z1.5 within GeneSpring. GO-Elite was
employed to assess significantly regulated gene ontology (GO) terms in the data
sets described above. At least 3 genes andZ10% genes in a GO term needed to be
changing with a permuted P value of r0.05 to be included. Microarray data are
available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress under
experiment E-MTAB-5086).
RNAseq studies. MutGCK mice were sacrificed 4 days after activation of the
transgene, the pancreas removed and islets isolated by collagenase digestion
followed by hand picking. RNA sequencing libraries were constructed from 200 ng
of total RNA isolated using the TruSeq RNA sample prep kit (Illumina). Single read
sequencing was performed on Illumina hiSeq2000 to 100 bp. Reads were aligned to
the mouse genome mm9 using RUM55. Read counts for RefSeq transcripts were
processed with EdgeR56 to generate fold changes and P values. P values were
converted to false discovery rates using the Benjamini & Hochberg mode of the
R function p.adjust. Differentially expressed genes were identified using an FDR
threshold of 10%. mRNA levels were expressed in reads per kilobase of transcript
per million mapped reads (RPKM). RNAseq data are available in the GEO database
(http://www.ncbi.nlm.nih.gov/geo accession number GSE86949).
qPCR. Total RNA was prepared from isolated islets using the RNeasy Lipid Tissue
Mini Kit (Qiagen) with an on-column DNase digestion step to remove genomic
DNA. RNA concentration was determined in triplicate using a NanoDrop
ND-1000 spectrophotometer (Thermo Scientific) and quality checked with an
Agilent Bioanalyzer. RNA was amplified using the Ovation Pico WTA System V2
(NuGen) kit and reversed transcribed. qPCR was performed using an Applied
Biosystems StepOne Plus Real-Time PCR system. Each reaction consisted of 2 ng
amplified cDNA, 0.5 ml Taqman probe, 10 ml Taqman Fast Advanced Master Mix,
and nuclease-free water (final volume of 15 ml). Transcript levels of metabolic genes
and the reference gene Actb quantified using Taqman probes (for probes see
Supplementary Table 2). The reaction cycle comprised an initial denaturation for
10min at 95 C, followed by 40 cycles of 95 C/15 s and 60 C/60 s. All reactions
were performed in triplicate. The StepOne Plus Real-Time PCR software
(Applied Biosystems) was used to measure threshold cycle (Ct) values. Gene
expression was determined using the Pfaffl method.
Western blotting. Proteins were extracted from INS-1 cells and islets isolated
from control or diabetic bV59M mice in RIPA lysis buffer (ThermoScientific)
containing protease inhibitor for 30min on ice. Samples were then centrifuged for
15min at 13,000 r.p.m. and 4 C, and supernatants used for blotting. Extracts were
separated on 4–12% SDS–polyacrylamide gels, blotted onto nitrocellulose
membranes, and assayed using specific antibodies (listed in Supplementary
Table 2). INS-1 cells were originally developed by Claes Wollheim (Geneva) and
kindly supplied by Jochen Lang (Bordeaux).
Serum lipid and glucose measurements. Whole blood was extracted, left to
stand at room temperature for 30min, and serum was then collected following
centrifugation at 5,000 g for 30min at 4 C. Commercially available kits were used
to measure HDL and LDL/VLDL cholesterol (Abcam; ab65390), triglycerides
(Abcam; ab65336), free fatty acids (ab65341) and alanine aminotransferase activity
(Sigma; MAK052). Serum glucose was measured using the Glucose (HK) Assay kit
(Sigma-Aldrich) as per the manufacturer’s instructions.
Electron microscopy. For routine structural analyses, pancreatic tissue or isolated
islets were fixed in 2.5% glutaraldehyde in 0.1M phosphate buffer for at least 1 h,
post-fixed in 1% osmium tetroxide, dehydrated in graded ethanol, and embedded
in Spurr’s resin. Ultrathin sections (70 nm) were cut onto Ni2þ grids, and, for
standard morphology, contrasted with 2% uranyl acetate and lead citrate. They
were examined in a Jeol 1010 microscope (Welwyn Garden City, UK) with an
accelerating voltage of 80 kV and a digital camera (Gatan, Ca, USA).
Specimens for immunolabelling were not osmicated, but dehydrated in graded
methanol and embedded in London Resin Gold resin (LRG) (Agar Scientific,
Stansted, UK) which was cured in UV light at  20 C overnight. Ultrathin
sections cut onto nickel grids were washed in 0.1M PBS containing egg albumin
(Sigma, UK) and incubated with primary antibodies at effective concentrations
(Supplementary Table 2). Antibody binding sites were identified using either
protein A gold (10 or 15 nm) (Biocell, Cardiff, UK) or biotin conjugated antibodies
(Dako) and streptavidin gold (10 or 15 nm) (Biocell). Sections were contrasted with
2% uranyl acetate and lead citrate and were examined in a Joel 1010 electron
microscope fitted with a digital camera (Gatan, Ca, USA).
Intracellular glycogen particles are not osmiophilic, are soluble in uranyl
acetate, and are not preserved by standard techniques57,58. To visualize glycogen,
therefore, islet cells were post-fixed in a mixture of 1% osmium and a saturated
solution of lead citrate (addition of 12.5% Reynolds lead citrate solution) in 0.1M
phosphate buffer for 1 h and processed as above into Spurr’s resin. Glycogen was
visualized using the periodic acid-thiosemicarbazide silver proteinate method
(Vye MV and Fischman DA 1971); 1% thiosemicarbazide (dissolved in 25%
acetic acid) and 1% silver proteinate (dissolved in water) (Elektron Technologies,
Stanstead UK) were prepared freshly for each experiment. Grids were not treated
with uranyl acetate or lead citrate for glycogen visualization.
Autophagosomes were defined as double-membrane vesicles containing
electron-dense membranes and other cytoplasmic material (Fig. 5h).
Immunostaining and morphometric analysis. Immunostaining was performed on
wax-embedded pancreatic sections fixed in 10% neutral-buffered formalin overnight
at 4 C. Dewaxed and rehydrated sections (5-mm thick) were blocked in 3% swine
serum for 30min at room temperature then incubated with primary antibodies
overnight at 4 C. Secondary fluorescent antibodies were incubated at room
temperature for 1 h and counterstained with DAPI for nuclear visualisation. For
antibodies, see Supplementary Table 3. PAS staining for glycogen was performed
using the Abcam kit (ab150680). Human surgical and post-mortem pancreatic
specimens were obtained with appropriate consent and with relevant UK local and
national ethics permissions (1986) and have been approved by the University of
Oxford.
ATP measurements. ATP levels were measured using the Roche Bioluminescence
assay kit HS II. Isolated islets were washed briefly in glucose-free RPMI media plus
10% FCS and 1% penicillin/streptomycin. Batches of 10 islets were incubated in test
solution for 2 h at 37 C and then lysed using the kit buffer at 25 C for 5min with
gentle shaking. ATP was measured according to the manufacturer’s instructions.
NAD(P)H measurements. NAD(P)H autofluorescence from isolated islets was
measured at 37 C either immediately following isolation (for 4-week diabetic
bV59M islets) or after 72h culture at different glucose concentrations
(control islets). Islets were cultured in RPMI media plus 10% FCS and 1%
penicillin/streptomycin at various glucose concentrations at 37C in a humidified
atmosphere of 5% CO2/95% air. Autofluorescence was excited at 350 nm and
emission measured between 400 and 500 nm. During recording, islets were con-
tinuously superfused with a solution containing (mM); 132 NaCl, 5.6 KCl, 2.6 CaCl2,
1.1 MgCl2, 1.2 NaH2PO4, 4.2 NaHCO3, 10 HEPES (pH 7.4) and glucose as indicated.
In some cases, experiments were terminated by application of FCCP (4mM), which
decreased NAD(P)H fluorescence in both control and mutant islets (not shown).
Traces were normalized to the signal obtained at the start of the recording in 1mM
glucose, to account for differences in islet size.
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INS-1 cell culture. INS-1 832-13 cells were cultured at 37C in a humidified
atmosphere of 5% CO2/95% air in RPMI (Gibco ref: 31870–025) supplemented
with: 10% FBS (Ref-10270–106; Lot-41F6 245C), 50 mM b-mercaptoethanol, 1mM
sodium pyruvate, 10mM HEPES, 1% pen/strep, 1% glutamax. The standard glu-
cose concentration was 11mM. For experiments, cells were seeded in 11mM
glucose for 24 h, and the media was then changed to 2mM or 25mM glucose for
24 h before harvesting. Knockdown of UGP2 was achieved using Lipofectamine
RNAiMAX (Invitrogen, CA, USA) and 20 pmoles siRNA directed against rat
UGP-2 (Invitrogen Silencer select RNAi). Stealth RNA interference siRNA
Negative Control Medium GC (Invitrogen) was used as a control. Following
knockdown for 72 h, cells were challenged for 48 h with 5mM or 25mM glucose
and mRNA and protein extracted.
Statistics. Data are mean values±s.e.m. of the indicated number of experiments.
Significance was tested using one-way ANOVA, Mann–Whitney U Test, Student’s
t-test, and a Bonferroni post hoc test applied, as indicated.
Data availability. Microarray data are available in the ArrayExpress database
(www.ebi.ac.uk/arrayexpress under experiment E-MTAB-5086). RNAseq
data can be found in the GEO database with accession number GSE86949
(http://www.ncbi.nlm.nih.gov/geo). The authors declare that all data supporting
the findings of this study are available within the paper (and its supplementary
information files) or can be obtained from the authors upon reasonable request.
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